The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Vaccination with Messenger RNA (mRNA)
Abstract
Both DNA and mRNA can be used as vehicles for gene therapy. Because the immune system is naturally activated by foreign nucleic acids thanks to the presence of Toll-like Receptors (TLR) in endosomes (TLR3, 7, and 8 detect exogenous RNA, while TLR9 can detect exogenous DNA), the delivery of foreign nucleic acids usually induces an immune response directed against the encoded protein. Many preclinical and clinical studies were performed using DNA-based experimental vaccines. However, no such products are yet approved for the human population. Meanwhile, the naturally transient and cytosolically active mRNA molecules are seen as a possibly safer and more potent alternative to DNA for gene vaccination. Optimized mRNA (improved for codon usage, stability, antigen-processing characteristics of the encoded protein, etc.) were demonstrated to be potent gene vaccination vehicles when delivered naked, in liposomes, coated on particles or transfected in dendritic cells in vitro. Human clinical trials indicate that the delivery of mRNA naked or transfected in dendritic cells induces the expected antigen-specific immune response. Follow-up efficacy studies are on the way. Meanwhile, mRNA can be produced in large amounts and GMP quality, allowing the further development of mRNA-based therapies. This chapter describes the structure of mRNA, its possible optimizations for immunization purposes, the different methods of delivery used in preclinical studies, and finally the results of clinical trial where mRNA is the active pharmaceutical ingredient of new innovative vaccines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, many of the obstacles to mRNA vaccine development have been surmounted, and recently there has been a revival in the use of nonamplifying mRNA vaccines for cancer (6), allergy (7), and gene therapy (8).”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [6]
In the citing paper
“Naturally transient and cytosolically active mRNA can now be produced at sufficient quantity and quality for human clinical trials (6) and is seen by many (9) as a safer and more potent alternative to pDNA for vaccination.”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [6]
In the citing paper
“In addition, long-term stability of RNA during storage has been demonstrated (6,40).”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [6]
In the citing paper
“The recent pioneering work of others (6) on the clinical production of smaller (∼2 kb) nonamplifying mRNA has established the feasibility of large-scale production of mRNA using an enzymatic transcription reaction.”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [6]
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
mRNA stability in mammalian cells
Ross, J. (1995) · Microbiological Reviews · doi:10.1128/mr.59.3.423-450.1995 · Cited by 1,411
Dannull, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25947 · Cited by 997
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
Boczkowski, D., Nair, S. K., Snyder, D., & Gilboa, E. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.465 · Cited by 915
Cationic liposome-mediated RNA transfection.
Malone, R. W., Felgner, P. L., & Verma, I. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6077 · Cited by 911
Regulation of Dendritic Cell Migration to the Draining Lymph Node
Martín-Fontecha, A., Sebastiani, S., Höpken, U. E., Uguccioni, M., Lipp, M., Lanzavecchia, A., & Sallusto, F. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030448 · Cited by 878
How do eucaryotic ribosomes select initiation regions in messenger RNA?
Kozak, M. (1978) · Cell · doi:10.1016/0092-8674(78)90039-9 · Cited by 833
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625
Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D., Dahm, P., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214364 · Cited by 562
Cited by
Sorted by citations
Items 101–132 of 132
Non-interfacial self-assembly of synthetic protocells
Xu, X., Guan, W., Yu, X., Xu, G., & Wang, C. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00402-w · Cited by 5
Ye, L., Liao, T., Deng, X., Long, H., Gai, L., Ke, W., & Huang, K. (2024) · New Biotechnology · doi:10.1016/j.nbt.2024.08.501 · Cited by 5
Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
Akamine, C. M., & Sahly, H. M. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.12.007 · Cited by 5
Nair, S. K., Boczkowski, D., Pruitt, S. K., & Urban, J. H. (2011) · Informa Healthcare eBooks · doi:10.3109/9781841848303.016 · Cited by 5
mRNA Vaccination and Personalized Cancer Therapy
Kreiter, S., Diken, M., & Şahin, U. (2014) · Springer eBooks · doi:10.1007/978-3-319-05104-8_9 · Cited by 3
The Characteristics of RNA Vaccine; its Strengths and Weaknesses
Park, H., Ko, H. L., Jung, S.-Y., Jo, H.-B., & Nam, J. (2016) · Journal of Bacteriology and Virology · doi:10.4167/jbv.2016.46.3.115 · Cited by 3
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy
De, W., Pollard, C., Vanham, G. L., & Rejm, J. (2012) · InTech eBooks · doi:10.5772/51583 · Cited by 3
Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic Cells
Benteyn, D., Heirman, C., Thielemans, K., & Bonehill, A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3625-0_7 · Cited by 2
Hussain, A., Wang, M., Yu, D., Zhang, J., Naseer, Q. A., Ullah, A., Essola, J. M., & Zhang, X. (2024) · Biomaterials Science · doi:10.1039/d4bm00561a · Cited by 2
DNA and RNA Vaccines for Prophylactic and Therapeutic Treatment of Type I Allergy
Weiss, R., Scheiblhofer, S., Rösler, E., & Thalhamer, J. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0439-2_12 · Cited by 1
RNA with chemotherapeutic base analogues as a dual-functional anti-cancer drug
Jarzębska, N. T., Tusup, M., Frei, J., Weiß, T., Holzinger, T., Mellett, M., Diken, M., Bredl, S., Weller, M., Speck, R. F., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2147665 · Cited by 1
Self-citationApplications of Spray-Dried Vaccines
Arpagaus, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-24323-3_6 · Cited by 2
Optic Neuritis following Second Administration of COVID-19 Vaccine: A Case Report
Saxton, E., Panchasara, B., & Sarangapani, S. (2023) · Case Reports in Ophthalmology · doi:10.1159/000531526 · Cited by 1
Thermodynamic Modeling of mRNA with the Addition of PrecipitantsPreprint
Tenberg, V., Walker, P. J., Inguva, P., Royo, M. D. C. P., Acevedo, A., Lin, V. S., Pang, M., Wang, Z., Myerson, A. S., & Braatz, R. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.18.683252 · Cited by 1
General Mechanisms of Gene Vaccines
Weiss, R., Tendeloo, V. F. V., Scheiblhofer, S., & Thalhamer, J. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0439-2_1
Recruiting the Host Defense Mechanisms: Roles for Vaccines and Chemotherapeutics
Schetters, T. P. M. (2009) · doi:10.1002/9783527626816.ch10
Moldenhauer, A. (2009) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-4865
Alternatives to Drug Development in the Apicomplexa
Schetters, T. P. M. (2011) · doi:10.1002/9783527633883.ch4
Development of nanosystems for HIV vaccine delivery
Matos, A. I. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Sichere und effiziente mRNA-Impfstoffe gegen SARS-CoV-2
Pascolo, S. (2020) · Bulletin des Médecins Suisses · doi:10.4414/saez.2020.19135
Self-citationCOVID-19 Pandemic: Analysis and Statistics of Confirmed Cases
Arceda, V. E. M., Arceda, M. A. M., & Laura, P. C. L. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98891
Sichere und effiziente mRNA-Impfstoffe gegen SARS-CoV-2
Pascolo, S. (2020) · Bulletin des Médecins Suisses · doi:10.4414/bms.2020.19135
Self-citationExperiments and Clinical Trials Against Infectious Diseases
Lemonnier, J., & Lemonnier, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-39300-6_12
Additional file 7 of Non-interfacial self-assembly of synthetic protocells
Xu, X., Guan, W., Yu, X., Xu, G., & Wang, C. (2023) · Figshare · doi:10.6084/m9.figshare.23621263
Additional file 2 of Non-interfacial self-assembly of synthetic protocells
Xu, X., Guan, W., Yu, X., Xu, G., & Wang, C. (2023) · Figshare · doi:10.6084/m9.figshare.23621248
Additional file 3 of Non-interfacial self-assembly of synthetic protocells
Xu, X., Guan, W., Yu, X., Xu, G., & Wang, C. (2023) · Figshare · doi:10.6084/m9.figshare.23621251
Additional file 4 of Non-interfacial self-assembly of synthetic protocells
Xu, X., Guan, W., Yu, X., Xu, G., & Wang, C. (2023) · Figshare · doi:10.6084/m9.figshare.23621254
Additional file 6 of Non-interfacial self-assembly of synthetic protocells
Xu, X., Guan, W., Yu, X., Xu, G., & Wang, C. (2023) · Figshare · doi:10.6084/m9.figshare.23621260
Additional file 5 of Non-interfacial self-assembly of synthetic protocells
Xu, X., Guan, W., Yu, X., Xu, G., & Wang, C. (2023) · Figshare · doi:10.6084/m9.figshare.23621257
Additional file 1 of Non-interfacial self-assembly of synthetic protocells
Xu, X., Guan, W., Yu, X., Xu, G., & Wang, C. (2023) · Figshare · doi:10.6084/m9.figshare.23621245
Metadata
- Authors
- Pascolo, S.
- Affiliations
- University of Tübingen (DE)
- Corresponding author
- Pascolo, Steve
- ORCID
- Pascolo, Steve
- Venue
- Handbook of Experimental Pharmacology
- Publisher
- Springer Berlin Heidelberg
- Published
- 2008
- Issue
- 183
- Pages
- 221-235
- ISSN
- 0171-2004 (ISSN-L)
- OpenAlex
- W81585652
- Cited by
- 126
- References
- 39
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 8 · 2022: 8 · 2021: 17 · 2020: 9 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 12 · 2015: 7 · 2014: 13 · 2013: 5 · 2012: 12
- FWCI
- 4.24
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Handbook of experimental pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- mRNA vaccines, mRNA delivery, Toll-like receptors, dendritic cell transfection, liposomal drug delivery, codon usage, mRNA structure, mRNA therapeutics
- MeSH terms
- Adjuvants, Immunologic, Animals, Clinical Trials as Topic, Dendritic Cells, Humans, Monocytes, RNA, Messenger, Transfection, Vaccines, Synthetic, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
